Thus, although the totality of data for M4205 indicates broad activity across KIT mutations and therefore potential effectiveness in patients with heterogeneous GIST tumor burden, the potential emergence of novel resistance mechanisms cannot be entirely ruled out and ongoing studies in patients will provide more insights (32). Here, KIT is linked to gastrointestinal stromal tumor.